Trial · NCT06931704
Comparison of Elranatamab and Lenalidomide Versus Daratumumab and Lenalidomide as Post-transplant Maintenance Therapy in Patients With Newly Diagnosed Myeloma (ElMMA)
NCT06931704, Phase 2, Not yet recruiting, Nantes University Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Comparison of Elranatamab and Lenalidomide Versus Daratumumab and Lenalidomide as Post-transplant Maintenance Therapy in Patients With Newly Diagnosed Myeloma (ElMMA). Trials, record NCT06931704. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06931704
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Comparison of Elranatamab and Lenalidomide Versus Daratumumab and Lenalidomide as Post-transplant Maintenance Therapy in Patients With Newly Diagnosed Myeloma (ElMMA)
- NCT number
- NCT06931704
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 176 participants, estimated
- Lead sponsor
- Nantes University Hospital
- Conditions
- Multiple Myeloma
- Interventions
- Elranatamab, Daratumumab, Lenalidomide
- First posted
- 2025-04-17
- Last updated
- 2025-04-23
Source ClinicalTrials.gov
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Minimal Residual Disease negativity rate | At the beginning of cycle 13 (each cycle is 28 days) | Minimal Residual Disease negativity rate (10-6, NGS) status after 12 cycles of maintenance |
| Secondary | Safety and tolerability of Dara-Len and Elra-Len | 4 years | Presence and severity of Treatment-Emergent Adverse Events defined by National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (Number of Treatment-Emergent Adverse Events), except for Cytokine Release Syndrome and Immune effector Cell-Associated Neurotoxicity syndrome, which will be assessed based on American Society for Transplantation and Cellular Therapy guidelines. |
| Secondary | Progression-free survival | 4 years | Progression-free survival, defined as the time from randomization to the first occurrence of Progressive Disease, or death from any cause, whichever occurs first. Subjects alive and for whom disease progression has not been observed will be censored at the last date of follow-up. |
| Secondary | Minimal Residual Disease negativity with the threshold evaluated at one year after randomisation | At the beginning of cycle 13 (each cycle is 28 days) | Rate of Minimal Residual Disease status at one year after randomisation |
| Secondary | Minimal Residual Disease negativity with the threshold evaluated at one two years | At the beginning of cycle 25 (each cycle is 28 days) | Rate of Minimal Residual Disease status at two years after randomization |
| Secondary | Sustained Minimal Residual Disease negativity | At the beginning of cycle 13 and 25 (each cycle is 28 days) | Rate of patients with Minimal Residual Disease negative status during at least 12 months (at least two consecutive times) |
| Secondary | Complete Response or better | 4 years | The rate of complete response or better as defined by International Myeloma Working Group 2016 |
| Secondary | Overall survival | 4 years | Time from randomisation to the date of death due to any cause. Subjects alive will be censored at the last date of follow-up. |
| Secondary | Progression-free survival 2 | 4 years | Time from randomization to either second line Progressive Disease (assessed by investigator on the first subsequent line of antimyeloma therapy) or death, whichever occurs first. Subjects alive and for whom a second disease progression has not been observed will be censored at the last date of follow-up. |
| Secondary | Ability of return to work | At the beginning of cycle 1 (each cycle is 28 days), at 3 months, 6 months, 12 months, 24 months, 36 months and 48 months | Ability of return to work assessed by a specific questionnaire |
1 to 10 of 13Source ClinicalTrials.gov
See all 13 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06931704
GET https://conductscience.org/api/trials/v1/NCT06931704/registered